Summary
BeOne Medicines Ltd. has demonstrated robust financial performance and significant pipeline progress in its 2025 annual report. The company achieved total global revenue of $5.3 billion, representing a 40.2% increase year-over-year, with a net income of $286.9 million. This growth was primarily driven by strong sales of BRUKINSA®, its leading Bruton's tyrosine kinase (BTK) inhibitor, which became the global market leader in B-cell malignancies and generated $3.9 billion in sales. The company also saw growth from TEVIMBRA®, its anti-PD-1 antibody, and its in-licensed products from Amgen. BeOne Medicines is strategically focused on expanding its differentiated hematology franchise with BRUKINSA, sonrotoclax (a next-generation BCL2 inhibitor with its first global approval in China), and its BTK chimeric degradation activation compound (BTK-CDAC). Sonrotoclax is currently under Priority Review by the FDA, with potential approval in the first half of 2026. The company's extensive clinical development programs, supported by its integrated global development "superhighway" and internal manufacturing capabilities, are designed to bring innovative and accessible treatments to patients worldwide.
Financial Highlights
50 data points| Revenue | $5.34B |
| Gross Profit | $4.67B |
| R&D Expenses | $2.15B |
| SG&A Expenses | $2.08B |
| Operating Expenses | $4.23B |
| Operating Income | $447.14M |
| Interest Expense | $49.95M |
| Net Income | $286.93M |
| EPS (Basic) | $0.20 |
| EPS (Diluted) | $0.19 |
| Shares Outstanding (Basic) | 1.42B |
| Shares Outstanding (Diluted) | 1.47B |
Key Highlights
- 1Achieved total global revenue of $5.3 billion, a 40.2% increase year-over-year, with net income of $286.9 million.
- 2BRUKINSA® sales reached $3.9 billion, becoming the global market leader in BTK inhibitors and demonstrating superior efficacy and lower cardiac toxicity compared to ibrutinib in the ALPINE trial.
- 3Sonrotoclax received its first global regulatory approval in China for R/R MCL and CLL/SLL, and is under FDA Priority Review for potential accelerated approval in the first half of 2026.
- 4TEVIMBRA® sales grew by 18.8% to $737.3 million, driven by expanded indications and reimbursement.
- 5Maintained a strong financial position with $4.5 billion in cash and cash equivalents and $1.0 billion in debt as of December 31, 2025.
- 6Advanced a diversified pipeline with five differentiated solid tumor New Molecular Entities (NMEs) entering the clinic in 2025, each with first-in-class or best-in-class potential.
- 7Invested $2.1 billion in R&D, a 9.9% increase year-over-year, supporting its pipeline advancement and internal development capabilities.